{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:35:06Z","timestamp":1793198106202,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":427,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1124\/jpet.122.001512","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T16:35:11Z","timestamp":1694795711000},"page":"180-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23"],"prefix":"10.1016","volume":"387","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-3642","authenticated-orcid":false,"given":"Boyd","family":"Steere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Beidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stu","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Kikly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Benschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001512_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.122.001512_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","article-title":"Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease","volume":"34","author":"Almradi","year":"2020","journal-title":"BioDrugs"},{"key":"10.1124\/jpet.122.001512_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cytogfr.2014.07.017","article-title":"IL-12-and IL-23 in health and disease","volume":"25","author":"Croxford","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1124\/jpet.122.001512_bib4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.201242598","article-title":"IL-23: one cytokine in control of autoimmunity","volume":"42","author":"Croxford","year":"2012","journal-title":"Eur J Immunol"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001512_bib5","doi-asserted-by":"crossref","first-page":"i028","DOI":"10.1093\/ecco-jcc\/jjab232.025","article-title":"OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the Phase 3 LUCENT-1 study","volume":"16","author":"D\u2019Haens","year":"2022","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1124\/jpet.122.001512_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.aidm.2015.04.002","article-title":"Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity","volume":"3","author":"El-Bassat","year":"2016","journal-title":"Advances in Digestive Medicine"},{"key":"10.1124\/jpet.122.001512_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1124\/jpet.122.001512_bib8","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1097\/MIB.0000000000000210","article-title":"Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-\u03b3+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease","volume":"20","author":"Globig","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1124\/jpet.122.001512_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001512_bib10","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001512_bib11","doi-asserted-by":"crossref","first-page":"S047","DOI":"10.1093\/ecco-jcc\/jjab073.048","article-title":"DOP09 mirikizumab-induced transcriptome changes in patient biopsies at week 12 are maintained through week 52 in patients with ulcerative colitis","volume":"15","author":"Johnson","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1124\/jpet.122.001512_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"10.1124\/jpet.122.001512_bib13","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001512_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"10.1124\/jpet.122.001512_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"10.1124\/jpet.122.001512_bib16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque PSORIASIS","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001512_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001512_bib18","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol"},{"key":"10.1124\/jpet.122.001512_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.122.001512_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.122.001512_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001512_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001512_bib23","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/ecco-jcc\/jjz203.104","article-title":"DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity","volume":"14","author":"Steere","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1124\/jpet.122.001512_bib24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/jpet.122.001512_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1359-6446(02)02590-4","article-title":"Optimization of protein therapeutics by directed evolution","volume":"8","author":"Vasserot","year":"2003","journal-title":"Drug Discov Today"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:51:12Z","timestamp":1740675072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524171066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0022356524171066"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001512","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}